Arecor Therapeutics plc

AIM:AREC Stock Report

Market Cap: UK£26.2m

Arecor Therapeutics Management

Management criteria checks 1/4

Arecor Therapeutics' CEO is Sarah Howell, appointed in Jun 2015, has a tenure of 9.5 years. total yearly compensation is £439.00K, comprised of 59.2% salary and 40.8% bonuses, including company stock and options. directly owns 2.3% of the company’s shares, worth £603.08K. The average tenure of the management team and the board of directors is 1.7 years and 7.3 years respectively.

Key information

Sarah Howell

Chief executive officer

UK£439.0k

Total compensation

CEO salary percentage59.2%
CEO tenure9.5yrs
CEO ownership2.3%
Management average tenure1.7yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

Jul 16
Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

Will Arecor Therapeutics (LON:AREC) Spend Its Cash Wisely?

Mar 15
Will Arecor Therapeutics (LON:AREC) Spend Its Cash Wisely?

CEO Compensation Analysis

How has Sarah Howell's remuneration changed compared to Arecor Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£9m

Mar 31 2024n/an/a

-UK£9m

Dec 31 2023UK£439kUK£260k

-UK£9m

Sep 30 2023n/an/a

-UK£9m

Jun 30 2023n/an/a

-UK£9m

Mar 31 2023n/an/a

-UK£9m

Dec 31 2022UK£421kUK£250k

-UK£9m

Sep 30 2022n/an/a

-UK£8m

Jun 30 2022n/an/a

-UK£7m

Mar 31 2022n/an/a

-UK£7m

Dec 31 2021UK£343kUK£218k

-UK£6m

Compensation vs Market: Sarah's total compensation ($USD552.50K) is above average for companies of similar size in the UK market ($USD347.66K).

Compensation vs Earnings: Sarah's compensation has increased whilst the company is unprofitable.

CEO

Sarah Howell (49 yo)

9.5yrs

Tenure

UK£439,000

Compensation

Dr. Sarah Jennifer Howell, Ph.D. has been the Chief Executive Officer of Arecor Therapeutics PLC since June 2015. Having joined in 2011 as Chief Operating Officer and Executive Director. During her time at...

Leadership Team

NamePositionTenureCompensationOwnership
Sarah Howell
CEO & Director9.5yrsUK£439.00k2.3%
£ 603.1k
David Ellam
Interim Chief Financial Officerless than a yearno datano data
Jan Jezek
Chief Scientific Officer17.9yrsno datano data
David Gerring
Senior Vice President of Development1.4yrsno datano data
Manjit Rahelu
Chief Business Officer1.7yrsno datano data

1.7yrs

Average Tenure

Experienced Management: AREC's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Sarah Howell
CEO & Director3.7yrsUK£439.00k2.3%
£ 603.1k
Christine Soden
Independent Non-Executive Director3.6yrsUK£40.00k0.051%
£ 13.3k
Alan Smith
Non-Executive Directorno dataUK£35.00k0.48%
£ 126.3k
Andrew John Richards
Non-Executive Chairman8.3yrsUK£80.00k0.59%
£ 155.6k
Mohammad Fazeli
Independent Non-Executive Director7.3yrsUK£35.00k0.31%
£ 80.4k
Bruce Buckingham
Member of Global Diabetes Scientific Advisory Board7.3yrsno datano data
Eda Cengiz
Member of Global Diabetes Scientific Advisory Board7.3yrsno datano data
Thomas Pieber
Member of Global Diabetes Scientific Advisory Board7.3yrsno datano data
Jeremy Lewis Morgan
Independent Non-Executive Director3.6yrsUK£40.00k0.072%
£ 18.9k

7.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: AREC's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 22:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arecor Therapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dr JuliePanmure Liberum
Julie SimmondsPanmure Liberum
Julie SimmondsPanmure Liberum Historic (Panmure Gordon)